Avonex

Showing 4 posts of 4 posts found.

bmssyracuseny

BMS’ Zeposia becomes first S1P receptor modulator available in Europe for relapsing remitting multiple sclerosis

May 28, 2020
Sales and Marketing Avonex, Bristol-Myers Squibb, EU, Europe, Zeposia, bristol myers squibb, multiple sclerosis

Bristol Myers Squibb is celebrating after its oral therapy Zeposia (ozanimod), secured European Commission for the treatment of relapsing remitting …

Biogen image

FDA approves Biogen’s long-acting MS drug

August 18, 2014
Sales and Marketing Avonex, Biogen, FDA, MS, Rebif, plegridy, tecfidera

Biogen Idec has racked up another approval over the weekend after its latest multiple sclerosis treatment Plegridy gained FDA backing. …

New MS drug shows promise for Abbott

August 10, 2011
Research and Development, Sales and Marketing Abbott, Avonex, Biogen, MS, gilenya

Biogen and Abbott’s multiple sclerosis drug daclizumab has performed well in a mid-stage trial, but two deaths marred the overall …

Abbott sign

Abbott starts head-to-head MS trial

May 25, 2010
Research and Development, Sales and Marketing Abbott, Avonex, Biogen, Gilena, daclizumab

Abbott has started enrolment for a phase III trial of daclizumab, a once-monthly injection for relapsing-remitting multiple sclerosis that it …

Latest content